Login
Israel-Hamas Conflict
World Cup
Social Media
Wrestling
Donald Trump
Music
Soccer
Instagram
Artificial Intelligence
Immigration
Cryptocurrency
Basketball
Glastonbury
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • Florence, Italy • Updated

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Summary by Globe Newswire
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the...

9 Articles

All
Left
7
Center
1
Right
1
Globe NewswireGlobe Newswire
+8 Reposted by 8 other sources
Center

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the...

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 78% of the sources lean Left
78% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Orangeville broke the news in Orangeville, Canada on Thursday, June 12, 2025.
Sources are mostly out of Canada (5)

Similar News Topics

Florence, Toscana icon

Florence, Toscana

Our use of cookies
Unlike other news sites, we do not share or sell your data to third-parties for targeted ads.
By continuing to use our application or website, you agree to our Terms of Service and Privacy Policy.
News
For You
SearchBlindspotLocal